ANTARES PHARMA, INC. 4
4 · ANTARES PHARMA, INC. · Filed Jun 5, 2013
Insider Transaction Report
Form 4
DAVE KAUSHIK J
Executive Vice President
Transactions
- Sale
Common Stock
2013-06-03$4.01/sh−48,000$192,547→ 265,028 total - Exercise/Conversion
Stock Option (right to buy)
2013-06-03−48,000→ 647,195 totalExercise: $0.47Exp: 2018-11-12→ Common Stock (48,000 underlying) - Exercise/Conversion
Common Stock
2013-06-03$0.47/sh+48,000$22,560→ 313,028 total
Footnotes (2)
- [F1]The stock option exercises and sales of common stock reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
- [F2]The options vested in equal quarterly installments over three years following the grant date.